Atacand For CHF: Can AstraZeneca CHARM FDA Into ACE Combo Approval?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca’s upcoming Atacand sNDA for use in heart failure will likely raise issues about conflicting data on another agent in the same class.